Drug Type Small molecule drug |
Synonyms NLX 219, NLX219 |
Target |
Action agonists |
Mechanism 5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC21H23ClF2N2O2 |
InChIKeyDXWRIDGYFFSIIY-UHFFFAOYSA-N |
CAS Registry2170404-93-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Depressive Disorder | Preclinical | Poland | 23 Apr 2025 | |
Parkinson Disease | Preclinical | Poland | 23 Apr 2025 |